Journal article
CASSETTE—clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation: Study protocol for a randomised controlled trial
Trials, Vol.20(1)
2019
Abstract
Background
Exotoxins are important virulence factors in Staphylococcus aureus. Clindamycin, a protein synthesis inhibitor antibiotic, is thought to limit exotoxin production and improve outcomes in severe S. aureus infections. However, randomised prospective data to support this are lacking.
Methods
An open-label, multicentre, randomised controlled trial (RCT) will compare outcome differences in severe S. aureus infection between standard treatment (flucloxacillin/cefazolin in methicillin-susceptible S. aureus; and vancomycin/daptomycin in methicillin-resistant S. aureus) and standard treatment plus an additional clindamycin given for 7 days. We will include a minimum of 60 participants (both adult and children) in the pilot study. Participants will be enrolled within 72 h of an index culture. Severe infections will include septic shock, necrotising pneumonia, or multifocal and non-contiguous skin and soft tissue/osteoarticular infections. Individuals who are immunosuppressed, moribund, with current severe diarrhoea or Clostridiodes difficile infection, pregnant, and those with anaphylaxis to β-lactams or lincosamides will be excluded.
The primary outcomes measure is the number of days alive and free (1 or 0) of systemic inflammatory response syndrome (SIRS) within the first 14 days post randomisation. The secondary outcomes measure will include all-cause mortality at 14, 42, and 90 days, time to resolution of SIRS, proportion with microbiological treatment failure, and rate of change of C-reactive protein over time. Impacts of inducible clindamycin resistance, strain types, methicillin susceptibility, and presence of various exotoxins will also be analysed.
Discussion
This study will assess the effect of adjunctive clindamycin on patient-centred outcomes in severe, toxin-mediated S. aureus infections. The pilot study will provide feasibility for a much larger RCT.
Trial registration
Australian New Zealand Clinical Trials Registry, ACTRN12617001416381p. Registered on 6 October 2017.
Details
- Title
- CASSETTE—clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation: Study protocol for a randomised controlled trial
- Authors/Creators
- R. Dotel (Author/Creator) - The University of SydneyS.Y.C. Tong (Author/Creator) - Peter Doherty InstituteA. Bowen (Author/Creator) - Princess Margaret Hospital for ChildrenJ.N. Nelson (Author/Creator) - Menzies School of Health ResearchM.V.N. O’Sullivan (Author/Creator)A.J. Campbell (Author/Creator) - Princess Margaret Hospital for ChildrenB.J. McMullan (Author/Creator) - Sydney Children's HospitalP.N. Britton (Author/Creator) - Children's Hospital at WestmeadJ.R. Francis (Author/Creator)D.P. Eisen (Author/Creator) - James Cook UniversityO. Robinson (Author/Creator) - Royal Perth HospitalL. Manning (Author/Creator) - Fiona Stanley HospitalJ.S. Davis (Author/Creator) - John Hunter Hospital
- Publication Details
- Trials, Vol.20(1)
- Publisher
- BioMed Central
- Identifiers
- 991005546019707891
- Copyright
- © 2019 The Author(s).
- Murdoch Affiliation
- School of Veterinary and Life Sciences
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
40 File views/ downloads
100 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.23 Antibiotics & Antimicrobials
- 1.23.173 MRSA and VRE
- Web Of Science research areas
- Medicine, Research & Experimental
- ESI research areas
- Clinical Medicine